Publications by authors named "Hyeyeon Yu"
Article Synopsis
- Lazertinib, a third-generation EGFR-tyrosine kinase inhibitor, was analyzed for its effectiveness in treating advanced EGFR T790M-positive non-small-cell lung cancer compared to osimertinib.
- The study involved 75 patients on lazertinib and 110 on osimertinib, but after matching for baseline characteristics, each group was reduced to 60 patients for fair comparison.
- Results showed that lazertinib had an objective response rate of 76.7% and a median progression-free survival of 12.3 months, which are similar to osimertinib but with the potential for better overall survival benefits.
JAMA Netw Open
February 2024
Article Synopsis
- The EXPLORE-LC initiative addresses the lack of comprehensive data on non-small cell lung cancer (NSCLC) by creating a common framework for research across various high-quality sources, aiming to enhance understanding of NSCLC and identify unmet needs in specific patient subgroups.
- A multicenter cohort study in South Korea evaluated clinical characteristics, treatment patterns, and overall survival of 22,101 NSCLC patients diagnosed from 2014 to 2019, using standardized data collection methods.
- Results showed that the majority of patients had nonsquamous NSCLC (78.5%), with significant insights into treatment outcomes and characteristics, highlighting demographic factors such as age and gender distribution in different NSCLC types.
JAMA Netw Open
March 2023
Article Synopsis
- Over the last decade, the treatment landscape for non-small cell lung cancer (NSCLC) has evolved significantly, but traditional clinical trials may not quickly capture the real-world outcomes of these advancements.
- This study aimed to analyze the outcomes of new NSCLC treatments by comparing survival rates and other variables from two time periods (2010-2015 and 2016-2020) in patients treated at Samsung Medical Center in Korea.
- The results revealed increased testing for molecular variations in adenocarcinoma patients and showed improved survival rates in the later period, indicating potential benefits from new therapies and testing protocols.
